Abraxane® or nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) is a 130nm nano particle formulation originally developed by Abraxis BioScience, receiving regulatory approval in from the FDA 2005 and in 2008 from the EMA for the treatment of breast cancer [6,13]. The gene discussed is ALB; the disease is breast carcinoma.